Once prevalent in North America, Oceania and Europe, incidence of this inflammatory bowel disease has been rising in newly industrialized countries in Africa, Asia and South America. This comprehensive report on Crohn’s Disease is available as a full-coverage report and as separate elements.
Full Disease Coverage Report
- Crohn’s Disease: Full Disease Coverage£17729.86Our 315-page exhaustively researched report delivers extensive coverage of this painful, often deadly disease. Includes an in-depth global market forecast, pipeline of products and treatments in development and on the market, as well as full-color charts and tables.
Or Buy as separate elements
- Crohn’s Disease: Epidemiology Report£2522.52This report covers disease background and causes, 20-year forecast and drivers of patient population. Provides robust market-by-market analysis of the diagnosed prevalent global disease population, data sources and research methods by geography and extensive bibliography.
- Crohn’s Disease: Forecast Report£3643.64In this report, Datamonitor Healthcare presents the results of its epidemiologic analyses of the diagnosed prevalent population of Crohn’s disease in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK), as well as a region-by-region forecast of diagnosed prevalent cases of CD.
- Crohn’s Disease: Marketed Drugs£5958.04This report examines the drugs currently on the market for CD, the major players, partners and approval dates, extensive product profiles of marketed drugs, a thorough drug assessment summary, and what to expect through 2035 and why.
- Crohn’s Disease: Pipeline Report£2592.59Understand the competition, new drugs on the horizon and the companies producing them, clinical trials in the making on a global scale by phase, and an analyst outlook of leading therapies based on surveys of gastroenterologists conducted by Datamonitor Healthcare.
- Crohn’s Disease: Treatment Report£3013.01This report covers current treatment options, preferred drugs and pharmacological prescribing rates for the US, Japan and five major EU markets, as well as the continued development of therapies to achieve long-term remission—still a significant unmet need.